Want to join the conversation?
$ACET said that its subsidiary Rising Pharmaceuticals is launching Olopatadine Hydrochloride 0.1% Ophthalmic Solution in U.S., generic version of Alcon's Patanol, which is used for the treatment of allergic conjunctivitis. According to IMS Health data, U.S. market sales for Olopatadine were about $223MM for the twelve months ended Sept. 30, 2015.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.